This project targets β-cell dysfunction, a central driver of both Type 1 and Type 2 Diabetes progression, by uniting experts from clinical medicine, bioinformatics, immunology, artificial intelligence, molecular biology, and translational therapeutics. Using multi-omic datasets from human cohorts and experimental models, advanced AI algorithms will identify molecular signatures, immune interactions, and metabolic stress pathways contributing to β-cell failure. Insights will be validated in preclinical systems and linked to clinical phenotypes, enabling the development of targeted therapeutic strategies. This integrated approach will uncover novel intervention points, inform biomarker discovery, and guide precision medicine strategies for preserving or restoring β-cell function. By combining cutting-edge computational science with laboratory and clinical expertise, the project will accelerate translation from discovery to therapeutic application, addressing an urgent unmet need in diabetes prevention and management.

Call for Partnerships:
We welcome partnerships with universities, health services, primary care networks, technology providers, government agencies, and community health organisations to provide data access, laboratory capacity, clinical expertise, and co-funding for translational research.